CompletedNCT01071707

Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Michigan
Principal Investigator: Herbert Reynolds, MD
National Heart, Lung and Blood Institute, Division of Lung Sciences, National Institute of Health
Enrollment: 108 enrolled
Eligibility: 35-80 years · All sexes
Timeline: 2009 – 2012

Study locations (9)

University of California, Los Angeles, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
National Jewish Medical and Research Center, Denver, Colorado, United States
University of Chicago, Chicago, Illinois, United States
University of Michigan, Ann Arbor, Michigan, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Temple University, Philadelphia, Pennsylvania, United States
Brown University, Providence, Rhode Island, United States
Vanderbilt University, Nashville, Tennessee, United States

Collaborators

National Heart, Lung, and Blood Institute (NHLBI) · National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01071707 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials